Get the Stockscreener App
2.43
0.00%
0.00
After Hours:
2.43
Akoya Biosciences Inc stock is traded at $2.43, with a volume of 61,213.
It is up +0.00% in the last 24 hours and up +10.96% over the past month.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
See More
Previous Close:
$2.43
Open:
$2.42
24h Volume:
61,213
Relative Volume:
0.27
Market Cap:
$120.44M
Revenue:
$96.63M
Net Income/Loss:
$-63.32M
P/E Ratio:
-1.6644
EPS:
-1.46
Net Cash Flow:
$-54.55M
1W Performance:
+1.67%
1M Performance:
+10.96%
6M Performance:
+14.08%
1Y Performance:
-45.27%
1-Day Range:
$2.39
$2.50
1-Week Range:
$2.26
$2.50
52-Week Range:
$1.88
$6.31
Akoya Biosciences Inc Stock (AKYA) Company Profile
Name
Akoya Biosciences Inc
Sector
Industry
Phone
855.896.8401
Address
100 CAMPUS DRIVE, MARLBOROUGH
Compare AKYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
2.43 | 120.44M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-06-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-06-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-21-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Feb-02-23 | Initiated | UBS | Buy |
| Nov-03-22 | Initiated | CapitalOne | Overweight |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Jun-22-22 | Initiated | BTIG Research | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| May-11-21 | Initiated | Canaccord Genuity | Buy |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Morgan Stanley | Overweight |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Akoya Biosciences Inc Stock (AKYA) Latest News
State Street Corp Boosts Position in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Grows By 20.7% - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Analysts - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 20.7% in December - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Sold by HighTower Advisors LLC - Defense World
Charles Schwab Investment Management Inc. Decreases Stake in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences updates director and officer indemnification agreements By Investing.com - Investing.com Canada
Akoya Biosciences updates director and officer indemnification agreements - Investing.com India
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 18.1% in November - Defense World
Market Cool On Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Pushing Shares 29% Lower - Simply Wall St
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Expands By 18.1% - MarketBeat
Akoya Biosciences and NeraCare Enter into an Exclusive - GlobeNewswire
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions - Marketscreener.com
Nature Methods Names Spatial Proteomics 'Method of the Year 2024'Akoya Biosciences Celebrates Industry Milestone - The Manila Times
Nature Methods Names Spatial Proteomics "Method of the Year - GlobeNewswire
Akoya's Spatial Proteomics Tech Crowned 'Method of the Year 2024' by Nature Methods - StockTitan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Akoya Biosciences' SWOT analysis: spatial proteomics firm faces headwinds - Investing.com India
Akoya Biosciences' SWOT analysis: spatial proteomics firm faces headwinds By Investing.com - Investing.com UK
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Piper Sandler Reiterates “Overweight” Rating for Akoya Biosciences (NASDAQ:AKYA) - Defense World
Akoya Biosciences stock target cut, rating held on recent earnings report - Investing.com Canada
Akoya Biosciences' (AKYA) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA) - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Akoya Biosciences shares target cut, maintains buy rating on Q3 results - Investing.com
Craig-Hallum Downgrades Akoya Biosciences (AKYA) - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold (NASDAQ:AKYA) - Seeking Alpha
Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $3.50 by Analysts at Canaccord Genuity Group - MarketBeat
Akoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Craig Hallum - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akoya Biosciences Shares Sink After FY24 Outlook Cut - MarketWatch
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 20.8% in October - MarketBeat
Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024 - Marketscreener.com
Akoya: Q3 Earnings Snapshot - Darien Times
Akoya Biosciences Reports Q3 2024 Financial Results - TipRanks
Akoya Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Akoya Biosciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? - Simply Wall St
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akoya Biosciences (AKYA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler®-Fusion 2.0 System and the new Phenocode™ Discovery IO60 Panel from Akoya Biosciences - PR Newswire
Akoya Biosciences Unveils a New Era in Spatial Content - GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel - Yahoo Finance
Akoya Biosciences Inc Stock (AKYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akoya Biosciences Inc Stock (AKYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
239,368 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Sale |
4.97 |
7,500 |
37,243 |
231,868 |
| McKelligon Brian | President and CEO |
Mar 13 '24 |
Sale |
4.94 |
7,500 |
37,035 |
224,368 |
2.64%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):